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Abstract: Objectives
Since the recognition of borderline ovarian tumours (BOT) in the 1970's the
management of this subset of epithelial ovarian tumours has presented a challenge to
clinicians. The majority present at an early stage but diagnosis is often only made
following surgery, hence the heterogeneity of surgical management. BOT are
morphologically diverse, and their behaviour is subsequently also heterogeneous. We
aimed to assess recurrence rates and the rate of malignant transformation in patients
diagnosed with BOT. Secondary objectives included a review current management and
assessment of tumour markers, stage, cyst dimensions and the presence of micro-
papillary features as prognostic indicators of recurrence.
Methods/materials
This retrospective cohort study included all patients treated with BOT between 2000
and 2015 in the South-east region of Scotland. Clinical, surgicopathological and follow-
up data were collated. Data were analysed with reference to recurrence and malignant
transformation.
Results
275 patients underwent treatment for BOT in the study period. Surgical management
was highly variable. A diagnosis of recurrent/persistent BOT or ovarian malignancy
following initial treatment of BOT was rare with only 12/275 (4%) cases. There were 7
(3%) cases of ovarian malignancy.  Advanced FIGO stage was the most prominent
prognostic factor. Elevated pre-operative serum CA125 and the presence of micro-
papillary features correlated with advanced stage at presentation.  With a lack of clear
guidance, follow up was highly variable with a median of 43 months (0 - 136).
Conclusions
To our knowledge this study is the largest BOT cohort in the UK. Recurrent disease is
rare in optimally staged, completely resected, early stage BOT, without high risk
features.  Caution is needed in women electing not to undergo completion staging after
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diagnosis and in those opting for a fertility-preserving approach. Thorough informed
consent and clear plans for surveillance and follow-up are needed with consideration of
delayed completion surgery as appropriate.
Response to Reviewers: We thank the reviewer for their comments regarding our manuscript ‘Borderline ovarian
tumours: Fifteen years’ experience at a Scottish tertiary cancer centre’.  We have
considered the comments and have amended the manuscript accordingly. In response
to the questions posed by the reviewer:
The results show a very high rate of laparotomy compared to laparoscopy: 90% versus
10%. How do the authors explain this rate?
1.We agree that the laparotomy rate in this series was higher (90%) than reported by
other groups.  The proportion of patients undergoing laparoscopy increased over the
15- year period, rising from 3% in the first 5 years to 16% in the final 5 years reflecting
a growing acceptance of the safety of this approach between 2000 - 2015.  The high
rate of laparotomy may also be a reflection of the relatively high median diameter of
tumours (16.5 cm) in this cohort compared to those reported in the literature examining
laparoscopic management of BOT (7.5 cm) and concern regarding rupture and
extraction of such large volume tumours 1.  Previous series examining cyst diameter
have suggested that laparoscopic management might be restricted to low volume cysts
2. We have added explanation of this to the discussion in lines 206-215.
What was the value of CA 19.9 in case of mucinous tumors?
2.Historically, CA 19.9 has not been used in the investigation of ovarian masses,
mucinous or other histological subtypes in Scotland and this is reflected in our national
guidelines (SIGN 135/ NICE).  We agree with the reviewer and acknowledge that
CA19.9 levels are commonly elevated in the presence of mucinous ovarian tumours
and can be useful in the diagnosis of peritoneal carcinomatosis originating from the
gastrointestinal tract.  Nevertheless, given that markedly elevated CA19.9 levels can
be found in benign mucinous disease 3, the routine use of CA19.9 to predict
histological subtype of ovarian mucinous tumours is not currently supported within the
NHS in Scotland.  As such we regret that this data is not available for the patients
within this retrospective cohort.
Why no frozen section has be done?
3.Resources within our regional public health system did not allow the regular provision
of resources for intraoperative frozen section (discussed in line 195 in the submitted
draft) in all hospitals included in the study throughout the study period and as such
management of BOT developed in the absence of this resource.  Furthermore,
historically there were concerns regarding the reliability and accuracy of frozen section
diagnosis of BOT.  With accumulating evidence and the provision of further resources
this is now regularly employed in our centre. Additionally, the role of frozen section for
the intra-operative diagnosis of borderline tumour must be carefully considered as it is
unlikely to affect the surgical procedure undertaken in the group of patients who do not
wish for a fertility sparing approach. In the setting of an isolated ovarian mass a frozen
section result of BOT would not justify routine lymph node dissection in addition to a
planned hysterectomy, BSO and omental biopsy. The histological subtyping of tumours
using frozen section is not always possible and the benefit of appendicectomy for a
macroscopically normal appendix in the setting of a mucinous BOT remains unclear.
We believe that frozen section is not adequately precise to dictate intra-operative
decision making regarding fertility decisions and it would be preferred in this subgroup
of patients to undertake a second procedure as necessary following full histology
reporting and opportunity for counselling. We have modified the discussion
accordingly, lines 195-205.
A table should be done to resume patients and tumours characteristics and surgery
procedure
4.We have included a table summarising the descriptive data of the patient cohort,
tumour characteristics and surgery undertaken.
The mean follow -up is short: 43 months explaining the low rate of recurrence (<4%).
5.We acknowledge the overall short length of formal follow-up of the cohort, with a
median of 43 months. This is skewed by the patients discharged to their general
practitioners without any hospital based follow-up and those who were discharged prior
to the traditional 5 years of follow-up, described in line 171. This variable practice is
perhaps a reflection of the lack of national guidance regarding recommended follow up
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
and of the movement towards patient-initiated follow up in the UK. In our health service
patients remain under the care of their general practitioner following discharge and with
a relatively established population with low rates of relocation we depend upon re-
referral to the treating centre if there is suspicion of recurrence.
Ovarian function was preserved only in 58 patients while 130 patients were pre-
menopausal. It represents a very low rate of conservative surgery.
6.We agree with the reviewer that this cohort demonstrates a relatively low rate of
conservative surgery (45%), although we note that this is higher than the large series
reported by the AGO group (28%) 4.  We suggest that the 15-year period over which
time this study was conducted has coincided with a shift towards more conservative
treatment for BOT as evidence of the safety of this approach has accumulated and
patient management earlier in the cohort may reflect a more radical approach to
treatment.  The decision to proceed with radical surgery is made by the patient
following careful counselling and with fully informed consent.  Ovarian preservation is
routinely presented as an option in pre-menopausal patients when appropriate and
these figures represent the healthcare choices of our population in real practice.
Why one patient received adjuvant chemotherapy for FIGO stage 3c SBOT while
invasive implants were excluded?
7.The decision-making process behind the administration of adjuvant chemotherapy to
a single patient with FIGO stage 3C SBOT is not clear.  This demonstrates the
limitations created by the retrospective nature of this study.  No invasive implants were
identified, and the patient underwent complete surgical staging with no residual
disease.   This was undertaken in 2008 and review of the patient’s records does not
provide further elucidation. We include the report of this patient for completeness of the
dataset.
In the conclusion the authors recommend to perform lymph node assessment in non-
mucinous borderline ovarian tumours while this has been disused and that this is not
free of morbidity.
8.We agree with the reviewer that there is no value in lymph node sampling or
complete dissection in BOT and this should therefore not be performed routinely.
Current UK guidelines, however suggest removal of bulky nodes and in keeping with
this we would encourage examination/palpation of lymph node chains to identify
enlarged nodes only. We also agree with the reviewer that a node dissection is not
without associated morbidity and this must therefore be judged on a case by case
basis. We have made amendments to the text in lines 275 onwards to give clarity on
this.
We thank the reviewer for the opportunity to discuss restaging surgery. We respectfully
disagree with their comments, with only sparse data in the literature in this regard.
Given the overall good prognosis of BOT demonstrating survival differences is difficult.
Data from the largest and most recent study in the literature (AGO) demonstrate a
significant increase in the risk of recurrence with each staging step omitted 5.  We
agree that in cases where thorough exploration of the abdominal cavity has been
undertaken at primary surgery then restaging is unlikely to significantly alter
management, however in those women with an incidental finding of BOT following
surgery by a non-gynaecological oncologist when complete abdominal exploration and
staging was not performed at primary surgery a restaging procedure should be
recommended. With regard to completion surgery, while no evidence suggests an
improvement in prognosis in our experience this discussion is often raised by patients
due to psychological stress and anxiety on completion of their family. We have added
additional text for further clarity from line 282.
We thank you for your further consideration of our manuscript for publication in your
journal.  We have amended the manuscript in light of the reviewer’s helpful comments
and believe, given the lack of RCT’s in BOT, data from our large case series is a
significant addition to the literature. Our series add to the limited data available and
supports counselling and decision making for clinicians, often non-gynaecological
oncologists, in the management of BOT.
Yours sincerely
James MayRachel O’Donnell
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Title Page
Borderline ovarian tumours: Fifteen years’ experience at a Scottish 
tertiary cancer centre 
Highlights 
 Management of borderline ovarian tumours is highly heterogeneous owing to variable patient, 
clinician and histological factors 
 Extent of staging at primary surgery is variable, rates of secondary completion staging are 
often low and follow-up is highly variable 
 Rates of recurrence and malignant transformation are exceptionally low but are higher with 
incomplete staging or incomplete resection  
 
Highlights (3 Highlights of no more than 100 characters each)
Borderline ovarian tumours: Fifteen years’ experience at a Scottish 
tertiary cancer centre 
Precis 
Borderline ovarian tumours constitute a diverse range of tumours with variable behaviour. Uncertainty 
exists regarding their optimal management. This study represents the largest UK study describing the 
challenges of management and follow up.   
Precis (no more than 200 characters)
Prof. Uziel Beller 
Editor in Chief, International Journal of Gynaecological Cancer 
  
9th July 2018 
 
Dear Professor Beller,  
We thank the reviewer for their comments regarding our manuscript ‘Borderline ovarian tumours: Fifteen years’ 
experience at a Scottish tertiary cancer centre’.  We have considered the comments and have amended the 
manuscript accordingly. In response to the questions posed by the reviewer: 
The results show a very high rate of laparotomy compared to laparoscopy: 90% versus 10%. How do the 
authors explain this rate? 
1. We agree that the laparotomy rate in this series was higher (90%) than reported by other groups.  The 
proportion of patients undergoing laparoscopy increased over the 15- year period, rising from 3% in 
the first 5 years to 16% in the final 5 years reflecting a growing acceptance of the safety of this approach 
between 2000 - 2015.  The high rate of laparotomy may also be a reflection of the relatively high median 
diameter of tumours (16.5 cm) in this cohort compared to those reported in the literature examining 
laparoscopic management of BOT (7.5 cm) and concern regarding rupture and extraction of such large 
volume tumours 1.  Previous series examining cyst diameter have suggested that laparoscopic 
management might be restricted to low volume cysts 2. We have added explanation of this to the 
discussion in lines 206-215.  
 
What was the value of CA 19.9 in case of mucinous tumors? 
2. Historically, CA 19.9 has not been used in the investigation of ovarian masses, mucinous or other 
histological subtypes in Scotland and this is reflected in our national guidelines (SIGN 135/ NICE).  We 
agree with the reviewer and acknowledge that CA19.9 levels are commonly elevated in the presence 
Response to Reviewers
of mucinous ovarian tumours and can be useful in the diagnosis of peritoneal carcinomatosis 
originating from the gastrointestinal tract.  Nevertheless, given that markedly elevated CA19.9 levels 
can be found in benign mucinous disease 3, the routine use of CA19.9 to predict histological subtype 
of ovarian mucinous tumours is not currently supported within the NHS in Scotland.  As such we 
regret that this data is not available for the patients within this retrospective cohort. 
 
Why no frozen section has be done? 
3. Resources within our regional public health system did not allow the regular provision of resources 
for intraoperative frozen section (discussed in line 195 in the submitted draft) in all hospitals included 
in the study throughout the study period and as such management of BOT developed in the absence 
of this resource.  Furthermore, historically there were concerns regarding the reliability and accuracy 
of frozen section diagnosis of BOT.  With accumulating evidence and the provision of further 
resources this is now regularly employed in our centre. Additionally, the role of frozen section for the 
intra-operative diagnosis of borderline tumour must be carefully considered as it is unlikely to affect 
the surgical procedure undertaken in the group of patients who do not wish for a fertility sparing 
approach. In the setting of an isolated ovarian mass a frozen section result of BOT would not justify 
routine lymph node dissection in addition to a planned hysterectomy, BSO and omental biopsy. The 
histological subtyping of tumours using frozen section is not always possible and the benefit of 
appendicectomy for a macroscopically normal appendix in the setting of a mucinous BOT remains 
unclear. We believe that frozen section is not adequately precise to dictate intra-operative decision 
making regarding fertility decisions and it would be preferred in this subgroup of patients to 
undertake a second procedure as necessary following full histology reporting and opportunity for 
counselling. We have modified the discussion accordingly, lines 195-205.  
 
A table should be done to resume patients and tumours characteristics and surgery procedure 
4. We have included a table summarising the descriptive data of the patient cohort, tumour 
characteristics and surgery undertaken.   
 The mean follow -up is short: 43 months explaining the low rate of recurrence (<4%). 
5. We acknowledge the overall short length of formal follow-up of the cohort, with a median of 43 
months. This is skewed by the patients discharged to their general practitioners without any hospital 
based follow-up and those who were discharged prior to the traditional 5 years of follow-up, 
described in line 171. This variable practice is perhaps a reflection of the lack of national guidance 
regarding recommended follow up and of the movement towards patient-initiated follow up in the 
UK. In our health service patients remain under the care of their general practitioner following 
discharge and with a relatively established population with low rates of relocation we depend upon 
re-referral to the treating centre if there is suspicion of recurrence.  
 
Ovarian function was preserved only in 58 patients while 130 patients were pre-menopausal. It 
represents a very low rate of conservative surgery. 
6. We agree with the reviewer that this cohort demonstrates a relatively low rate of conservative 
surgery (45%), although we note that this is higher than the large series reported by the AGO group 
(28%) 4.  We suggest that the 15-year period over which time this study was conducted has coincided 
with a shift towards more conservative treatment for BOT as evidence of the safety of this approach 
has accumulated and patient management earlier in the cohort may reflect a more radical approach 
to treatment.  The decision to proceed with radical surgery is made by the patient following careful 
counselling and with fully informed consent.  Ovarian preservation is routinely presented as an option 
in pre-menopausal patients when appropriate and these figures represent the healthcare choices of 
our population in real practice. 
 
Why one patient received adjuvant chemotherapy for FIGO stage 3c SBOT while invasive implants were 
excluded? 
7. The decision-making process behind the administration of adjuvant chemotherapy to a single patient 
with FIGO stage 3C SBOT is not clear.  This demonstrates the limitations created by the retrospective 
nature of this study.  No invasive implants were identified, and the patient underwent complete 
surgical staging with no residual disease.   This was undertaken in 2008 and review of the patient’s 
records does not provide further elucidation. We include the report of this patient for completeness 
of the dataset.   
In the conclusion the authors recommend to perform lymph node assessment in non-mucinous 
borderline ovarian tumours while this has been disused and that this is not free of morbidity. 
8. We agree with the reviewer that there is no value in lymph node sampling or complete dissection in 
BOT and this should therefore not be performed routinely.  Current UK guidelines, however suggest 
removal of bulky nodes and in keeping with this we would encourage examination/palpation of lymph 
node chains to identify enlarged nodes only. We also agree with the reviewer that a node dissection is 
not without associated morbidity and this must therefore be judged on a case by case basis. We have 
made amendments to the text in lines 275 onwards to give clarity on this.  
We thank the reviewer for the opportunity to discuss restaging surgery. We respectfully disagree with 
their comments, with only sparse data in the literature in this regard. Given the overall good 
prognosis of BOT demonstrating survival differences is difficult.  Data from the largest and most 
recent study in the literature (AGO) demonstrate a significant increase in the risk of recurrence with 
each staging step omitted 5.  We agree that in cases where thorough exploration of the abdominal 
cavity has been undertaken at primary surgery then restaging is unlikely to significantly alter 
management, however in those women with an incidental finding of BOT following surgery by a non-
gynaecological oncologist when complete abdominal exploration and staging was not performed at 
primary surgery a restaging procedure should be recommended. With regard to completion surgery, 
while no evidence suggests an improvement in prognosis in our experience this discussion is often 
raised by patients due to psychological stress and anxiety on completion of their family. We have 
added additional text for further clarity from line 282.  
 
We thank you for your further consideration of our manuscript for publication in your journal.  We have 
amended the manuscript in light of the reviewer’s helpful comments and believe, given the lack of RCT’s in 
BOT, data from our large case series is a significant addition to the literature. Our series add to the limited data 
available and supports counselling and decision making for clinicians, often non-gynaecological oncologists, in 
the management of BOT.    
 
Yours sincerely 
                 
James May  Rachel O’Donnell 
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Borderline ovarian tumours: Fifteen years’ experience at a Scottish tertiary 
cancer centre 
Abstract 
 
Objectives 5 
Since the recognition of borderline ovarian tumours (BOT) in the 1970’s the management of this subset of 
epithelial ovarian tumours has presented a challenge to clinicians. The majority present at an early stage 
but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. 
BOT are morphologically diverse, and their behaviour is subsequently also heterogeneous. We aimed to 
assess recurrence rates and the rate of malignant transformation in patients diagnosed with BOT. 10 
Secondary objectives included a review of current management and assessment of tumour markers, stage, 
cyst dimensions and the presence of micro-papillary features as prognostic indicators of recurrence.  
Methods 
This retrospective cohort study included all patients treated with BOT between 2000 and 2015 in the South-
east region of Scotland. Clinical, surgicopathological and follow-up data were collated. Data were analysed 15 
with reference to recurrence and malignant transformation.  
Results  
275 patients underwent treatment for BOT in the study period. Surgical management was highly variable. 
A diagnosis of recurrent/persistent BOT or ovarian malignancy following initial treatment of BOT was rare 
with only 12/275 (4%) cases. There were 7 (3%) cases of ovarian malignancy. Advanced FIGO stage was 20 
the most prominent prognostic factor. Elevated pre-operative serum CA125 and the presence of micro-
papillary features correlated with advanced stage at presentation.  With a lack of clear guidance, follow up 
was highly variable with a median of 43 months (0 - 136).  
Conclusions 
To our knowledge this study is the largest BOT cohort in the UK. Recurrent disease is rare in optimally 25 
staged, completely resected, early stage BOT, without high risk features.  Caution is needed in women 
electing not to undergo completion staging after diagnosis and in those opting for a fertility-preserving 
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approach. Thorough informed consent and clear plans for surveillance and follow-up are needed with 
consideration of delayed completion surgery as appropriate.  
 30 
Word count: 298 
Keywords: 
Borderline ovarian tumours 
Ovarian tumours of low malignant potential  
Prognosis 35 
Recurrence / relapse 
Malignant transformation 
 
3 
 
Introduction 40 
Borderline ovarian tumours (BOT) or tumours of low malignant potential, first described by Taylor in 1929 
1, account for 10 - 15% of all epithelial ovarian tumours.  Characterised by cellular features of malignancy, 
they do not show destructive stromal invasion and thus fall short of the criteria of invasive cancer 2-4. BOTs 
are one of the more controversial topics in gynaecology oncology given that their behaviour is not always 
entirely benign. The management and follow-up of this subset of epithelial ovarian tumours presents a 45 
challenge to clinicians with few clinical studies in recent decades to address these.  There is clear guidance 
for the investigation and management of invasive ovarian cancer 5 but guidance for the management of 
BOT is less well established due to a relative paucity of evidence. In the 2010 Cochrane review, only 7 
trials were evaluated with only one including a comparison of surgical approaches 6. Debate persists 
regarding conservative surgical approaches, surveillance and the role of delayed completion surgery. 50 
Consequently, surgical approaches continue to vary due to individual surgeon opinion, patient preference 
and the broad spectrum of histological findings within this subset of ovarian tumours.  
 
BOT cannot reliably be differentiated from benign or malignant disease pre-operatively. Subsequently, a 
range of specialists are involved in the provision of care, contributing to highly variable management. 55 
Historically, BOT had been described as a precursor of ovarian carcinoma and was consequently treated 
in the same way in an attempt to avoid recurrent invasive disease 7. During recent decades, many 
observational studies have shown a radical operative approach, including lymphadenectomy, does not offer 
significant advantage in terms of relapse or survival 8,9.  Several studies have concluded that fertility sparing 
surgery may be appropriate for some patients10,11, though a small, well-defined risk of recurrence persists 60 
in women treated conservatively 12-14.  
 
The 10-year survival is reported to be 99% for stage I, 98% for stage II, 96% for stage III and 77% for stage 
IV 14-18. Whilst the prognosis can be seen to be favourable in the majority, a proportion of women do 
succumb to their disease and therefore provision of accurate counselling and correct management is 65 
critical.  
4 
 
 
In the absence of a randomised controlled trial to address these many unanswered questions regarding 
optimum management of BOT we rely upon data from case series to facilitate appropriate counselling of 
patients. This study aimed to report the rate of recurrence and malignant transformation in a large series of 70 
BOT patients over a 15-year period in Scotland to define prognostic indicators of recurrence to guide follow-
up protocol.  
Materials and Methods 
The Southeast of Scotland Cancer Network (SCAN) is centred on the Royal Infirmary of Edinburgh, UK, 
the major gynaecological oncology centre for the south-east region of Scotland, serving a population of 1.4 75 
million. This observational study included all patients with pathologically proven BOT diagnosed between 
2000 and 2015. Patients were prospectively registered on the SCAN database.  As a service evaluation 
this study is exempt from the requirement for research ethical review.   
 
BOT were defined using four histological characteristics 19: (i) epithelial proliferation with/without the 80 
formation of microscopic papillary projections; (ii) atypical epithelial activity with no more than 4 mitotic 
figures per 10 high power field 20; (iii) mild or moderate atypicality of the nuclei; (iv) isolated eosinophilic 
cells or cells clusters within the stroma, resembling the epithelial cells lining the surface of papillae, not 
exceeding 5mm in the largest diameter 21. Lymph node involvement was defined as one or more lymph 
nodes containing a borderline epithelial proliferation closely resembling the BOT without invasion of the 85 
capsule 19. Patients with invasive deposits were excluded in keeping with current classification of these 
tumours as low-grade serous carcinoma 21. All patients underwent central pathological review. 
 
Clinical, surgicopathological, follow-up and survival data were collated from the MDT database, patient 
medical records, pathology database and Information Services Division Scotland. Histopathological data 90 
included FIGO stage (1998), subtype, cyst dimensions and volume. Volume (V) was calculated using the 
following equation: V = (l x w x d) x 0.523 where l, w, and d are the geometric length, width, and depth of 
5 
 
the cyst, respectively. Primary treatment was defined as treatment before or immediate treatment after 
referral to SCAN.  
 95 
Staging was considered complete if surgery included bilateral salpingo-oophorectomy (BSO), omental and 
peritoneal biopsies, cytology and, in cases of mucinous BOT (MBOT), appendicectomy.  Hysterectomy and 
lymphadenectomy were not considered necessary for complete staging as per British Gynaecological 
Cancer Society guidelines 5.   
 100 
Recurrence was defined as histological evidence of a tumour resembling the original pathology without 
invasion more than 6 months following primary surgery and malignant transformation as a tumour 
resembling the original pathology with invasion or distant metastases more than 6 months following primary 
surgery. Progression free survival (PFS) and overall survival (OS) were calculated from the date of 
diagnosis.  Fisher’s exact test was used to compare categorical variables.  Continuous variables were 105 
compared using the Student’s t test.  Pearson’s correlation coefficient was used to determine two-way linear 
associations.  All statistical analysis was performed using GraphPad Prism Software (Version 7.03 for 
Windows, La Jolla, California, USA).  
Results 
In total 275 patients were treated for BOT during the study period. The median age at diagnosis was 52 110 
years (17 – 88).  130 (47%) patients were pre-menopausal, of which 42 (32%) were nulliparous. 229 (83%) 
patients presented with clinical symptoms, the remainder (16%) were diagnosed incidentally during 
unrelated medical investigations.  All patients underwent primary surgical treatment (90% laparotomy, 10% 
laparoscopy), (Table 1).  
 115 
Most tumours were of an MBOT subtype (155/275, 56%) with 111 (40%) reported as serous borderline 
(SBOT). There were 3 (1%) cases of endometrioid BOT (EBOT), 4 were classified as mixed seromucinous 
(mxBOT) type and two without clear classification. Tumours were bilateral in 45 (16%) cases, of which 40 
(89%) cases were SBOT. More than 80% (228/275) of tumours were diagnosed at early stage (≤ FIGO 
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Stage1C), 4% (11/275) Stage 2, 8% (21/275) Stage 3 and 1 case of Stage 4 disease.  Cysts varied greatly 120 
in size with a median cyst diameter of 16.5 cm (3 – 50 cm).  Median cyst diameter was higher in MBOT (20 
cm) than SBOT (11 cm), (p<0.0001). Cyst volume was also highly variable with a median of 585 cm3, (2 - 
16,631 cm3).  Median cyst volume was higher in MBOT (971 cm3) than SBOT (181 cm3), (p=0.0013).  Pre-
operative CA125 was higher for SBOT (median, 73 KU/L) in comparison to MBOT (median, 32 KU/L), 
(p<0.001), Figure 1, A. 125 
 
The extent of surgery was highly variable.  Ovarian function was preserved in 58 (21%) patients of whom 
11 (19%) underwent ovarian cystectomy and the remainder unilateral salpingo-oophorectomy (USO).  
Staging was complete at primary surgery in 94/275 (34%) cases. This varied according to histology with 
60% (67/111) of women with SBOT completely staged at primary surgery compared to 16% (25/155) 130 
patients with MBOT and 67% (2/3) EBOT.  Only 25/155 (16%) of MBOT underwent appendicectomy.  
Secondary procedures for purposes of completion staging were undertaken in 24 patients following which 
staging was complete in 104/275 (38%) cases. Ten patients underwent second surgical procedures for 
suspected recurrence of which 7 were confirmed as recurrent disease and 3 benign.  One patient received 
adjuvant chemotherapy (6 cycles of carboplatin and paclitaxel) after complete staging surgery for a FIGO 135 
stage 3C SBOT with non-invasive implants, following review at the gynaecology oncology MDT. 
 
Recurrent or persistent BOT as well as malignant transformation, following initial treatment of BOT, was 
identified in 12/275 (4%) cases (Ttable 21).  Median PFS was 14 months (1 - 36). Four patients developed 
recurrent borderline disease (3 SBOT, 1 MBOT), all were asymptomatic.  Three cases were diagnosed on 140 
clinical examination or ultrasound during routine follow up, one was an incidental finding at the time of a 
hernia repair.   One further patient was considered to have persistent disease, presenting with abdominal 
pain 3 months post operatively following surgery for FIGO stage 3A SBOT with residual disease described 
at initial surgery.  All 5 patients were managed surgically and had no further episodes of disease recurrence 
with median FU of 43 months (32 - 201). 145 
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Seven patients were diagnosed with an ovarian malignancy following an initial diagnosis of BOT of which 
5 died during follow up (Table 2).  The median OS in this group was 50 months (8 - 136).  All patients 
presented symptomatically. Not all cases can be easily classified as recurrent disease or malignant 
transformation arising from BOT. Two patients presented within 6 months of primary surgery, both had 150 
equivocal original pathology and although formerly classified as a BOT, they were acknowledged to be at 
least at the malignant end of the continuous spectrum of BOT. One patient was incompletely staged and 
the other had residual disease following primary surgery. Two ovarian malignancies were diagnosed, for 
which BOT is not recognised to be a precursor lesion.  One patient, diagnosed with FIGO stage 1A MBOT 
following USO (with biopsy of contralateral, omental biopsy, lymph node sampling and appendicectomy), 155 
presented with disseminated Sertoli Leydig tumour 7 months postoperatively. Another patient, found to 
have an incidental, unilateral SBOT following risk reducing BSO for a BRCA1 mutation, was later diagnosed 
with high grade serous primary peritoneal carcinoma. 
 
There was positive correlation between pre-operative CA125 and increasing FIGO stage of tumour, Figure 160 
1, B, (r = 0.182, p=0.005).  CEA was significantly higher in MBOT in comparison to the serous subtypes 
(p=0.008).  There was no significant correlation between CEA and FIGO stage (r = 0.072, p=0.468), Figure 
1, C and D. There was positive correlation between FIGO stage at presentation and risk of 
recurrent/persistent disease (r=0.236, p=0.0002) and positive correlation between the presence of micro-
papillary features on histology and FIGO stage of disease (r=0.993, p=0.073), Error! Reference source not 165 
found. Micro-papillary features were no more prevalent (4/12, 33%) in patients who recurred in comparison 
to patients without documented recurrence (75/263, 29%), (p=0.748).  Micro-invasion was seen in 1/12 
(8%) of those cases who recurred in comparison to 12/263 (5%) of those that who did not (p=0.446). A 
correlation of r=0.844 (p=0.360) was seen between presence of micro-invasion and stage of disease.  
Preservation of ovarian function was more common in patients who recurred (p=0.039).  170 
 
The duration and frequency of follow-up was not consistent with substantial variation.  Median follow-up for 
the entire cohort was 43 months (0 – 136). Twenty-three (8%) patients had no follow-up and were 
8 
 
discharged to their GP immediately following surgery. Eighteen remain alive with no recurrent disease 
identified, the remaining 5 died of causes unrelated to BOT. 175 
Discussion 
This study represents the largest UK series of BOT and in addition to providing valuable data, highlights 
the lack of consensus about both treatment and follow-up resulting in variability of surgical management 
and post-operative follow-up.  While the retrospective nature of our data is acknowledged as a limitation, it 
offers the opportunity to reflect on the changing nature of practice within the 15-year study period. 180 
 
In our study, stage at presentation was correlated with risk of recurrence.  The number of patients 
completely staged at primary surgery was low (34%). Only 24 women underwent secondary surgery for 
completion of staging. Due to the retrospective nature of the study it was difficult to determine if the low rate 
of secondary surgery was due to patient choice or variation in management between individual surgeons.  185 
Secondary surgery for staging purposes exposes patients to further surgical and anaesthetic risk, yet 
omission of thorough staging, particularly in women undergoing fertility sparing surgery, precludes valuable 
prognostic information. Data from the AGO ROBOT study demonstrated the importance of complete 
staging, with an increase in recurrence risk for each surgical staging step omitted 22.  In our study, the most 
commonly omitted step in staging was appendicectomy with only 16% of women with MBOT undergoing 190 
this procedure.  While appendicectomy is commonly performed in the staging of MBOT, data from several 
studies do not support this practice in the presence of a macroscopically normal appendix 23,24.  The value 
of secondary surgery for the purposes of appendicectomy alone is therefore unclear.   
 
Intraoperative frozen section, not utilised in this cohort as this service was not routinely available 195 
throughout this series (2000 - 2015), has been demonstrated to have reasonable specificity in the 
diagnosis of BOT.  The additional resources needed for frozen section must be considered but may be 
offset by the potential reduction in the need for secondary staging surgery in patients with invasive and 
borderline disease, particularly when a conservative approach is desired.  It must be acknowledged that a 
significant proportion of women thought to have borderline disease on frozen section will be classified as 200 
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malignant on final pathology creating potential for under staging in serous malignant disease if 
lymphadenectomy is not undertaken 25,26. Complex decisions regarding loss of fertility in premenopausal 
women are therefore preferably made following accurate diagnosis based upon formal pathology review 
of paraffin embedded material and we would encourage a 2-step procedure in such patients to ensure 
adequate and specific counselling. 205 
While the laparoscopic approach to BOT has not been evaluated in a randomized trial, evidence from 
retrospective series suggest that a laparoscopic approach is not associated with an increase in the risk of 
recurrence 27. The number of patients undergoing laparotomy in this series was higher (90%) than reported 
by other groups 28. The proportion of patients undergoing laparoscopy increased over the 15- year period, 
rising from 3% in the first 5 years to 16% in the final 5 years reflecting acceptance of the safety of this 210 
approach. The high rate of laparotomy may reflect the relatively high median diameter of tumours (16.5 cm) 
in this cohort compared to those reported in the literature examining laparoscopic management of BOT (7.5 
cm) 27 and concern regarding rupture and extraction of such large volume tumours. Previous series 
examining cyst diameter have suggested that laparoscopic management might be restricted to low volume 
cysts 29. 215 
 
In this study, 12% of women were aged 40 years or younger and nulliparous at the time of diagnosis, 
representing a sub population in whom potential randomisation in the setting of a clinical trial presents clear 
difficulties. Consistent with published data, ovarian preservation was more prevalent in women who 
subsequently developed recurrent disease compared those that did not.  Relapse rates are reported to be 220 
higher after cystectomy (12 – 58%) and unilateral salpingo-oophorectomy (0 – 20%) compared with patients 
who have undergone complete staging surgery (2.5 – 5.7%) 30. There is little published to address the rate 
of conception and live birth rate following conservative management of BOT. Palomba et al reported a 
significantly higher conception rate in women undergoing bilateral cystectomy for bilateral SBOT in 
comparison to USO and contralateral cystectomy 31. After 128 months of follow up, patients treated with 225 
the more conservative approach had improved outcomes in terms of live birth rates, however there was a 
significantly shorter time to relapse and need for completion surgery. No significant difference in the number 
of recurrences was identified and no deaths occurred 11. 
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The overall rate of malignant relapse was 3% in our series; this is in keeping with du Bois et al who reported 230 
malignant relapse in 2.3% of a series of 950 patients 32.  The risk of recurrence and malignant transformation 
is highly variable between studies with a reported mean of 3% ranging from 0 – 58% 33.  This may in part 
be due to the inconsistent approach to completion surgery for staging and the recognised intra-/inter-
observer variation in the histological reporting of BOT emphasising the importance of central pathological 
review by an expert gynaecological pathologist 34.    235 
 
This study supports available evidence regarding prognostic indicators for risk of recurrence/malignant 
transformation. Advanced FIGO stage was the most prominent prognostic factor identified.  Micropapillary 
features and microinvasion were not independently associated with increased recurrence risk. The 
presence of micro-papillary features was correlated with advanced stage at presentation.  There was a 240 
significant correlation between elevated CA125 and stage at presentation. Advanced FIGO stage, 
microinvasion, presence of implants, as well as micropapillary pattern have been reported by some as risk 
factors for extra-ovarian disease and recurrence, but this is not consistent in the literature 35-38. These 
features should be used for the identification of women at highest risk of recurrence facilitating provision of 
appropriate counselling, consideration of completion surgery and/or close follow-up. Conversely, fertility 245 
sparing surgery should be reserved for women with early stage disease in the absence of poor prognostic 
indicators with the option of staging surgery following completion of a family.   
 
The follow up of patients within this series was highly variable perhaps reflecting the lack of national 
consensus regarding optimal practice. In the changing face of traditional hospital based follow up in the UK, 250 
with a move towards patient-led, non-hospital based follow-up programmes; individualised strategies based 
on available prognostic information may be required.  Patients with advanced stage disease and women in 
whom complete staging has not been performed require close surveillance.  In our study, all patients 
subsequently diagnosed with malignancy, presented symptomatically. Detection of asymptomatic 
recurrence by transvaginal ultrasound has been demonstrated by several authors 11. In one case series 255 
follow-up ultrasound detected the abnormality in all patients in whom recurrence occurred (n=28) 12.  These 
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recurrences were associated with an abnormal physical vaginal examination in 57% of cases and an 
elevated CA125 in 33% 12,33. Recurrent borderline disease that is detected early is usually easily resectable 
and consequently carries an excellent prognosis 39. In our series, 3 women underwent surgery for presumed 
recurrence which was confirmed as benign disease. The potential for intensive surveillance to increase 260 
intervention for benign disease should be considered along with the resource implications of repeated 
imaging. Recurrences as late as 23 and 25 years after initial diagnosis have been reported and the optimum 
duration of follow up is not clear 40. In women with Stage 1A/1B disease with optimal surgery and the 
absence of high risk prognostic factors, recurrence is rare, and consideration should be given to discharge 
from long-term follow-up, after discussion with the patient. For women with FIGO stage 1C or above, those 265 
in whom staging has been incomplete or where fertility has been conserved, long-term follow-up should be 
recommended which may include ultrasound, CA125 and clinical examination. The linear pattern of 
recurrence described in some studies suggests that an intense follow-up regimen may not be needed and 
with a lack of evidence to dictate best practice, annual follow-up may be appropriate.  
 270 
We propose that all cases of BOT are discussed at a tertiary cancer centre including central review of 
pathology.  Where possible patients with moderate or high RMI should have surgery undertaken in a tertiary 
cancer centre where full surgical staging can be undertaken. The availability of intra-operative frozen 
section should be used where available to guide the extent of excision/staging undertaken at initial surgery. 
A frozen section result demonstrating BOT should prompt complete staging including consideration of 275 
lymph node assessment in non-mucinous disease, and appendicectomy in MBOT 5.  Although Nno survival 
benefit has been shown with lymphadenectomy in BOT and systematic lymphadenectomy or lymph node 
sampling should not be routinely performed.  Intraoperative examination of lymph nodes should be 
considered such that, in accordance with current UK guidelines 5, enlarged lymph nodes only may be 
removed, lymph node assessment . 5would ensure that cases of early invasive disease are fully staged 41. 280 
Secondary surgery for restaging, if the initial operation was incomplete, should be recommended requires 
careful counselling.  Several studies indicate an inferior outcome in inadequately staged patients 27,28.  Data 
from the AGO ROBOT study highlight an increase in the recurrence risk for each staging procedure omitted 
with 14.6% of patients upstaged following restaging procedures 22. While retrospective series have 
12 
 
suggested that restaging does not have a significant impact on patient management having failed to 285 
demonstrate any improvement in overall survival 42 others suggest restaging is associated with improved 
PFS in higher risk cohorts 43. Restaging surgery is most relevant to those women with an incidental finding 
of BOT following surgery by a non-gynaecological oncologist when complete abdominal exploration and 
staging was not performed at primary surgery and should be recommended in these circumstances.  
 290 
Completion surgery in women undergoing fertility preservation should may be discussed when fertility is no 
longer desired although it should be emphasised that there are no data suggesting this impacts on overall 
survival or progression free survival. Decisions regarding secondary surgery and surgery in the context of 
fertility preservation are complex and recruitment to a prospective randomised trial presents significant 
difficulties. Given the variation in current practice, publication of data from other UK centres would allow 295 
meta-analysis of larger numbers, providing more robust data to guide patient counselling and decision 
making. We therefore propose the initiation of a UK wide database to help inform future patient care.  
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Borderline ovarian tumours: Fifteen years’ experience at a Scottish tertiary 
cancer centre 
Abstract 
 
Objectives 5 
Since the recognition of borderline ovarian tumours (BOT) in the 1970’s the management of this subset of 
epithelial ovarian tumours has presented a challenge to clinicians. The majority present at an early stage 
but their diagnosis is often only made following surgery, hence the heterogeneity of surgical management. 
BOT are morphologically diverse, and their behaviour is subsequently also heterogeneous. We aimed to 
assess recurrence rates and the rate of malignant transformation in patients diagnosed with BOT. 10 
Secondary objectives included a review of current management and assessment of tumour markers, stage, 
cyst dimensions and the presence of micro-papillary features as prognostic indicators of recurrence.  
Methods 
This retrospective cohort study included all patients treated with BOT between 2000 and 2015 in the South-
east region of Scotland. Clinical, surgicopathological and follow-up data were collated. Data were analysed 15 
with reference to recurrence and malignant transformation.  
Results  
275 patients underwent treatment for BOT in the study period. Surgical management was highly variable. 
A diagnosis of recurrent/persistent BOT or ovarian malignancy following initial treatment of BOT was rare 
with only 12/275 (4%) cases. There were 7 (3%) cases of ovarian malignancy. Advanced FIGO stage was 20 
the most prominent prognostic factor. Elevated pre-operative serum CA125 and the presence of micro-
papillary features correlated with advanced stage at presentation.  With a lack of clear guidance, follow up 
was highly variable with a median of 43 months (0 - 136).  
Conclusions 
To our knowledge this study is the largest BOT cohort in the UK. Recurrent disease is rare in optimally 25 
staged, completely resected, early stage BOT, without high risk features.  Caution is needed in women 
electing not to undergo completion staging after diagnosis and in those opting for a fertility-preserving 
Manuscript (All Manuscript Text Pages in MS Word format,
including References and Figure Legends)
2 
 
approach. Thorough informed consent and clear plans for surveillance and follow-up are needed with 
consideration of delayed completion surgery as appropriate.  
 30 
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Introduction 40 
Borderline ovarian tumours (BOT) or tumours of low malignant potential, first described by Taylor in 1929 
1, account for 10 - 15% of all epithelial ovarian tumours.  Characterised by cellular features of malignancy, 
they do not show destructive stromal invasion and thus fall short of the criteria of invasive cancer 2-4. BOTs 
are one of the more controversial topics in gynaecology oncology given that their behaviour is not always 
entirely benign. The management and follow-up of this subset of epithelial ovarian tumours presents a 45 
challenge to clinicians with few clinical studies in recent decades to address these.  There is clear guidance 
for the investigation and management of invasive ovarian cancer 5 but guidance for the management of 
BOT is less well established due to a relative paucity of evidence. In the 2010 Cochrane review, only 7 
trials were evaluated with only one including a comparison of surgical approaches 6. Debate persists 
regarding conservative surgical approaches, surveillance and the role of delayed completion surgery. 50 
Consequently, surgical approaches continue to vary due to individual surgeon opinion, patient preference 
and the broad spectrum of histological findings within this subset of ovarian tumours.  
 
BOT cannot reliably be differentiated from benign or malignant disease pre-operatively. Subsequently, a 
range of specialists are involved in the provision of care, contributing to highly variable management. 55 
Historically, BOT had been described as a precursor of ovarian carcinoma and was consequently treated 
in the same way in an attempt to avoid recurrent invasive disease 7. During recent decades, many 
observational studies have shown a radical operative approach, including lymphadenectomy, does not offer 
significant advantage in terms of relapse or survival 8,9.  Several studies have concluded that fertility sparing 
surgery may be appropriate for some patients10,11, though a small, well-defined risk of recurrence persists 60 
in women treated conservatively 12-14.  
 
The 10-year survival is reported to be 99% for stage I, 98% for stage II, 96% for stage III and 77% for stage 
IV 14-18. Whilst the prognosis can be seen to be favourable in the majority, a proportion of women do 
succumb to their disease and therefore provision of accurate counselling and correct management is 65 
critical.  
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In the absence of a randomised controlled trial to address these many unanswered questions regarding 
optimum management of BOT we rely upon data from case series to facilitate appropriate counselling of 
patients. This study aimed to report the rate of recurrence and malignant transformation in a large series of 70 
BOT patients over a 15-year period in Scotland to define prognostic indicators of recurrence to guide follow-
up protocol.  
Materials and Methods 
The Southeast of Scotland Cancer Network (SCAN) is centred on the Royal Infirmary of Edinburgh, UK, 
the major gynaecological oncology centre for the south-east region of Scotland, serving a population of 1.4 75 
million. This observational study included all patients with pathologically proven BOT diagnosed between 
2000 and 2015. Patients were prospectively registered on the SCAN database.  As a service evaluation 
this study is exempt from the requirement for research ethical review.   
 
BOT were defined using four histological characteristics 19: (i) epithelial proliferation with/without the 80 
formation of microscopic papillary projections; (ii) atypical epithelial activity with no more than 4 mitotic 
figures per 10 high power field 20; (iii) mild or moderate atypicality of the nuclei; (iv) isolated eosinophilic 
cells or cells clusters within the stroma, resembling the epithelial cells lining the surface of papillae, not 
exceeding 5mm in the largest diameter 21. Lymph node involvement was defined as one or more lymph 
nodes containing a borderline epithelial proliferation closely resembling the BOT without invasion of the 85 
capsule 19. Patients with invasive deposits were excluded in keeping with current classification of these 
tumours as low-grade serous carcinoma 21. All patients underwent central pathological review. 
 
Clinical, surgicopathological, follow-up and survival data were collated from the MDT database, patient 
medical records, pathology database and Information Services Division Scotland. Histopathological data 90 
included FIGO stage (1998), subtype, cyst dimensions and volume. Volume (V) was calculated using the 
following equation: V = (l x w x d) x 0.523 where l, w, and d are the geometric length, width, and depth of 
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the cyst, respectively. Primary treatment was defined as treatment before or immediate treatment after 
referral to SCAN.  
 95 
Staging was considered complete if surgery included bilateral salpingo-oophorectomy (BSO), omental and 
peritoneal biopsies, cytology and, in cases of mucinous BOT (MBOT), appendicectomy.  Hysterectomy and 
lymphadenectomy were not considered necessary for complete staging as per British Gynaecological 
Cancer Society guidelines 5.   
 100 
Recurrence was defined as histological evidence of a tumour resembling the original pathology without 
invasion more than 6 months following primary surgery and malignant transformation as a tumour 
resembling the original pathology with invasion or distant metastases more than 6 months following primary 
surgery. Progression free survival (PFS) and overall survival (OS) were calculated from the date of 
diagnosis.  Fisher’s exact test was used to compare categorical variables.  Continuous variables were 105 
compared using the Student’s t test.  Pearson’s correlation coefficient was used to determine two-way linear 
associations.  All statistical analysis was performed using GraphPad Prism Software (Version 7.03 for 
Windows, La Jolla, California, USA).  
Results 
In total 275 patients were treated for BOT during the study period. The median age at diagnosis was 52 110 
years (17 – 88).  130 (47%) patients were pre-menopausal, of which 42 (32%) were nulliparous. 229 (83%) 
patients presented with clinical symptoms, the remainder (16%) were diagnosed incidentally during 
unrelated medical investigations.  All patients underwent primary surgical treatment (90% laparotomy, 10% 
laparoscopy), (Table 1).  
 115 
Most tumours were of an MBOT subtype (155/275, 56%) with 111 (40%) reported as serous borderline 
(SBOT). There were 3 (1%) cases of endometrioid BOT (EBOT), 4 were classified as mixed seromucinous 
(mxBOT) type and two without clear classification. Tumours were bilateral in 45 (16%) cases, of which 40 
(89%) cases were SBOT. More than 80% (228/275) of tumours were diagnosed at early stage (≤ FIGO 
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Stage1C), 4% (11/275) Stage 2, 8% (21/275) Stage 3 and 1 case of Stage 4 disease.  Cysts varied greatly 120 
in size with a median cyst diameter of 16.5 cm (3 – 50 cm).  Median cyst diameter was higher in MBOT (20 
cm) than SBOT (11 cm), (p<0.0001). Cyst volume was also highly variable with a median of 585 cm3, (2 - 
16,631 cm3).  Median cyst volume was higher in MBOT (971 cm3) than SBOT (181 cm3), (p=0.0013).  Pre-
operative CA125 was higher for SBOT (median, 73 KU/L) in comparison to MBOT (median, 32 KU/L), 
(p<0.001), Figure 1, A. 125 
 
The extent of surgery was highly variable.  Ovarian function was preserved in 58 (21%) patients of whom 
11 (19%) underwent ovarian cystectomy and the remainder unilateral salpingo-oophorectomy (USO).  
Staging was complete at primary surgery in 94/275 (34%) cases. This varied according to histology with 
60% (67/111) of women with SBOT completely staged at primary surgery compared to 16% (25/155) 130 
patients with MBOT and 67% (2/3) EBOT.  Only 25/155 (16%) of MBOT underwent appendicectomy.  
Secondary procedures for purposes of completion staging were undertaken in 24 patients following which 
staging was complete in 104/275 (38%) cases. Ten patients underwent second surgical procedures for 
suspected recurrence of which 7 were confirmed as recurrent disease and 3 benign.  One patient received 
adjuvant chemotherapy (6 cycles of carboplatin and paclitaxel) after complete staging surgery for a FIGO 135 
stage 3C SBOT with non-invasive implants, following review at the gynaecology oncology MDT. 
 
Recurrent or persistent BOT as well as malignant transformation, following initial treatment of BOT, was 
identified in 12/275 (4%) cases (Table 2).  Median PFS was 14 months (1 - 36). Four patients developed 
recurrent borderline disease (3 SBOT, 1 MBOT), all were asymptomatic.  Three cases were diagnosed on 140 
clinical examination or ultrasound during routine follow up, one was an incidental finding at the time of a 
hernia repair.   One further patient was considered to have persistent disease, presenting with abdominal 
pain 3 months post operatively following surgery for FIGO stage 3A SBOT with residual disease described 
at initial surgery.  All 5 patients were managed surgically and had no further episodes of disease recurrence 
with median FU of 43 months (32 - 201). 145 
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Seven patients were diagnosed with an ovarian malignancy following an initial diagnosis of BOT of which 
5 died during follow up (Table 2).  The median OS in this group was 50 months (8 - 136).  All patients 
presented symptomatically. Not all cases can be easily classified as recurrent disease or malignant 
transformation arising from BOT. Two patients presented within 6 months of primary surgery, both had 150 
equivocal original pathology and although formerly classified as a BOT, they were acknowledged to be at 
least at the malignant end of the continuous spectrum of BOT. One patient was incompletely staged and 
the other had residual disease following primary surgery. Two ovarian malignancies were diagnosed, for 
which BOT is not recognised to be a precursor lesion.  One patient, diagnosed with FIGO stage 1A MBOT 
following USO (with biopsy of contralateral, omental biopsy, lymph node sampling and appendicectomy), 155 
presented with disseminated Sertoli Leydig tumour 7 months postoperatively. Another patient, found to 
have an incidental, unilateral SBOT following risk reducing BSO for a BRCA1 mutation, was later diagnosed 
with high grade serous primary peritoneal carcinoma. 
 
There was positive correlation between pre-operative CA125 and increasing FIGO stage of tumour, Figure 160 
1, B, (r = 0.182, p=0.005).  CEA was significantly higher in MBOT in comparison to the serous subtypes 
(p=0.008).  There was no significant correlation between CEA and FIGO stage (r = 0.072, p=0.468), Figure 
1, C and D. There was positive correlation between FIGO stage at presentation and risk of 
recurrent/persistent disease (r=0.236, p=0.0002) and positive correlation between the presence of micro-
papillary features on histology and FIGO stage of disease (r=0.993, p=0.073), Error! Reference source not 165 
found. Micro-papillary features were no more prevalent (4/12, 33%) in patients who recurred in comparison 
to patients without documented recurrence (75/263, 29%), (p=0.748).  Micro-invasion was seen in 1/12 
(8%) of those cases who recurred in comparison to 12/263 (5%) of those that who did not (p=0.446). A 
correlation of r=0.844 (p=0.360) was seen between presence of micro-invasion and stage of disease.  
Preservation of ovarian function was more common in patients who recurred (p=0.039).  170 
 
The duration and frequency of follow-up was not consistent with substantial variation.  Median follow-up for 
the entire cohort was 43 months (0 – 136). Twenty-three (8%) patients had no follow-up and were 
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discharged to their GP immediately following surgery. Eighteen remain alive with no recurrent disease 
identified, the remaining 5 died of causes unrelated to BOT. 175 
Discussion 
This study represents the largest UK series of BOT and in addition to providing valuable data, highlights 
the lack of consensus about both treatment and follow-up resulting in variability of surgical management 
and post-operative follow-up.  While the retrospective nature of our data is acknowledged as a limitation, it 
offers the opportunity to reflect on the changing nature of practice within the 15-year study period. 180 
 
In our study, stage at presentation was correlated with risk of recurrence.  The number of patients 
completely staged at primary surgery was low (34%). Only 24 women underwent secondary surgery for 
completion of staging. Due to the retrospective nature of the study it was difficult to determine if the low rate 
of secondary surgery was due to patient choice or variation in management between individual surgeons.  185 
Secondary surgery for staging purposes exposes patients to further surgical and anaesthetic risk, yet 
omission of thorough staging, particularly in women undergoing fertility sparing surgery, precludes valuable 
prognostic information. Data from the AGO ROBOT study demonstrated the importance of complete 
staging, with an increase in recurrence risk for each surgical staging step omitted 22.  In our study, the most 
commonly omitted step in staging was appendicectomy with only 16% of women with MBOT undergoing 190 
this procedure.  While appendicectomy is commonly performed in the staging of MBOT, data from several 
studies do not support this practice in the presence of a macroscopically normal appendix 23,24.  .   
 
Intraoperative frozen section, not utilised in this cohort as this service was not routinely available 
throughout this series (2000 - 2015), has been demonstrated to have reasonable specificity in the 195 
diagnosis of BOT.  The additional resources needed for frozen section must be considered but may be 
offset by the potential reduction in the need for secondary staging surgery in patients with invasive and 
borderline disease, particularly when a conservative approach is desired.  It must be acknowledged that a 
significant proportion of women thought to have borderline disease on frozen section will be classified as 
malignant on final pathology creating potential for under staging in serous malignant disease if 200 
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lymphadenectomy is not undertaken 25,26. Complex decisions regarding loss of fertility in premenopausal 
women are therefore preferably made following accurate diagnosis based upon formal pathology review 
of paraffin embedded material and we would encourage a 2-step procedure in such patients to ensure 
adequate and specific counselling. 
While the laparoscopic approach to BOT has not been evaluated in a randomized trial, evidence from 205 
retrospective series suggest that a laparoscopic approach is not associated with an increase in the risk of 
recurrence 27. The number of patients undergoing laparotomy in this series was higher (90%) than reported 
by other groups 28. The proportion of patients undergoing laparoscopy increased over the 15- year period, 
rising from 3% in the first 5 years to 16% in the final 5 years reflecting acceptance of the safety of this 
approach. The high rate of laparotomy may reflect the relatively high median diameter of tumours (16.5 cm) 210 
in this cohort compared to those reported in the literature examining laparoscopic management of BOT (7.5 
cm) 27 and concern regarding rupture and extraction of such large volume tumours. Previous series 
examining cyst diameter have suggested that laparoscopic management might be restricted to low volume 
cysts 29. 
 215 
In this study, 12% of women were aged 40 years or younger and nulliparous at the time of diagnosis, 
representing a sub population in whom potential randomisation in the setting of a clinical trial presents clear 
difficulties. Consistent with published data, ovarian preservation was more prevalent in women who 
subsequently developed recurrent disease compared those that did not.  Relapse rates are reported to be 
higher after cystectomy (12 – 58%) and unilateral salpingo-oophorectomy (0 – 20%) compared with patients 220 
who have undergone complete staging surgery (2.5 – 5.7%) 30. There is little published to address the rate 
of conception and live birth rate following conservative management of BOT. Palomba et al reported a 
significantly higher conception rate in women undergoing bilateral cystectomy for bilateral SBOT in 
comparison to USO and contralateral cystectomy 31. After 128 months of follow up, patients treated with 
the more conservative approach had improved outcomes in terms of live birth rates, however there was a 225 
significantly shorter time to relapse and need for completion surgery. No significant difference in the number 
of recurrences was identified and no deaths occurred 11. 
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The overall rate of malignant relapse was 3% in our series; this is in keeping with du Bois et al who reported 
malignant relapse in 2.3% of a series of 950 patients 32.  The risk of recurrence and malignant transformation 230 
is highly variable between studies with a reported mean of 3% ranging from 0 – 58% 33.  This may in part 
be due to the inconsistent approach to completion surgery for staging and the recognised intra-/inter-
observer variation in the histological reporting of BOT emphasising the importance of central pathological 
review by an expert gynaecological pathologist 34.    
 235 
This study supports available evidence regarding prognostic indicators for risk of recurrence/malignant 
transformation. Advanced FIGO stage was the most prominent prognostic factor identified.  Micropapillary 
features and microinvasion were not independently associated with increased recurrence risk. The 
presence of micro-papillary features was correlated with advanced stage at presentation.  There was a 
significant correlation between elevated CA125 and stage at presentation. Advanced FIGO stage, 240 
microinvasion, presence of implants, as well as micropapillary pattern have been reported by some as risk 
factors for extra-ovarian disease and recurrence, but this is not consistent in the literature 35-38. These 
features should be used for the identification of women at highest risk of recurrence facilitating provision of 
appropriate counselling, consideration of completion surgery and/or close follow-up. Conversely, fertility 
sparing surgery should be reserved for women with early stage disease in the absence of poor prognostic 245 
indicators with the option of staging surgery following completion of a family.   
 
The follow up of patients within this series was highly variable perhaps reflecting the lack of national 
consensus regarding optimal practice. In the changing face of traditional hospital based follow up in the UK, 
with a move towards patient-led, non-hospital based follow-up programmes; individualised strategies based 250 
on available prognostic information may be required.  Patients with advanced stage disease and women in 
whom complete staging has not been performed require close surveillance.  In our study, all patients 
subsequently diagnosed with malignancy, presented symptomatically. Detection of asymptomatic 
recurrence by transvaginal ultrasound has been demonstrated by several authors 11. In one case series 
follow-up ultrasound detected the abnormality in all patients in whom recurrence occurred (n=28) 12.  These 255 
recurrences were associated with an abnormal physical vaginal examination in 57% of cases and an 
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elevated CA125 in 33% 12,33. Recurrent borderline disease that is detected early is usually easily resectable 
and consequently carries an excellent prognosis 39. In our series, 3 women underwent surgery for presumed 
recurrence which was confirmed as benign disease. The potential for intensive surveillance to increase 
intervention for benign disease should be considered along with the resource implications of repeated 260 
imaging. Recurrences as late as 23 and 25 years after initial diagnosis have been reported and the optimum 
duration of follow up is not clear 40. In women with Stage 1A/1B disease with optimal surgery and the 
absence of high risk prognostic factors, recurrence is rare, and consideration should be given to discharge 
from long-term follow-up, after discussion with the patient. For women with FIGO stage 1C or above, those 
in whom staging has been incomplete or where fertility has been conserved, long-term follow-up should be 265 
recommended which may include ultrasound, CA125 and clinical examination. The linear pattern of 
recurrence described in some studies suggests that an intense follow-up regimen may not be needed and 
with a lack of evidence to dictate best practice, annual follow-up may be appropriate.  
 
We propose that all cases of BOT are discussed at a tertiary cancer centre including central review of 270 
pathology.  Where possible patients with moderate or high RMI should have surgery undertaken in a tertiary 
cancer centre where full surgical staging can be undertaken. The availability of intra-operative frozen 
section should be used where available to guide the extent of excision/staging undertaken at initial surgery. 
A frozen section result demonstrating BOT should prompt complete staging   No survival benefit has been 
shown with lymphadenectomy in BOT and systematic lymphadenectomy or lymph node sampling should 275 
not be routinely performed.  Intraoperative examination of lymph nodes should be considered such that, in 
accordance with current UK guidelines 5, enlarged lymph nodes only may be removed .  
Secondary surgery for restaging, if the initial operation was incomplete, requires careful counselling.  
Several studies indicate an inferior outcome in inadequately staged patients 27,28.  Data from the AGO 
ROBOT study highlight an increase in the recurrence risk for each staging procedure omitted with 14.6% 280 
of patients upstaged following restaging procedures 22. While retrospective series have suggested that 
restaging does not have a significant impact on patient management having failed to demonstrate any 
improvement in overall survival 41 others suggest restaging is associated with improved PFS in higher risk 
cohorts 42. Restaging surgery is most relevant to those women with an incidental finding of BOT following 
12 
 
surgery by a non-gynaecological oncologist when complete abdominal exploration and staging was not 285 
performed at primary surgery and should be recommended in these circumstances.  
 
Completion surgery in women undergoing fertility preservation may be discussed when fertility is no longer 
desired although it should be emphasised that there are no data suggesting this impacts on overall survival 
or progression free survival. Decisions regarding secondary surgery and surgery in the context of fertility 290 
preservation are complex and recruitment to a prospective randomised trial presents significant difficulties. 
Given the variation in current practice, publication of data from other UK centres would allow meta-analysis 
of larger numbers, providing more robust data to guide patient counselling and decision making. We 
therefore propose the initiation of a UK wide database to help inform future patient care.  
 295 
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Legends to figures and tables 
Figure 1: CA125 and CEA levels by histological subtype and correlation with FIGO stage 400 
Figure 2:Correlation between micropapillary features and FIGO stage of borderline ovarian tumour at 
presentation 
Table 1: Cohort demographics 
Table 2: Detailed patient demographics of 12 patients with recurrent BOT or malignant transformation 
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Figure 1. CA125 and CEA levels by histological subtype and correlation with FIGO stage.
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Figure 2: Correlation between micropapillary features and FIGO stage of disease at presentation
Figure
Characteristics n =275 
Median age (range) 52 (17-88) 
Histology  
Serous 111 (40%) 
Mucinous 155 (56%) 
Seromucinous 4 (1%) 
Endometrioid 3 (1%) 
Unclassified 2 (1%) 
FIGO stage at Diagnosis  
I 228 (80%) 
II  11 (4%) 
III 21 (8%) 
IV 1 (0.5%) 
Histological Features  
Micropapillary features 79 (29%) 
Microinvasion 13 (5%) 
Surgical Approach  
Laparotomy 247 (90%) 
Laparoscopy 28 (10%) 
Complete staging at primary surgery 94 (34%) 
Ovarian function preservation 58 (21%) 
Ovarian cystectomy 11 
Unilateral salpingo-oophorectomy 47 
Surgical Procedures  
Ovarian cystectomy 11 (4%) 
Unilateral salpingo-oophorectomy 71 (26%) 
Bilateral salpingo-oophorectomy 190 (69%) 
Hysterectomy 169 (61%) 
Table 1. Baseline characteristics and surgical procedures 
Table 1
Age 
(years) 
Pre-
operative 
CA125 
(U/ ml) 
Primary Surgery 
Histological 
subtype 
FIGO 
Stage 
Micropapilliary 
features 
Progression 
Free Survival 
(months) 
Presentation of 
Recurrence 
Recurrence/malignant 
transformation 
Management 
Patient 
status 
Follow up 
(months) 
Recurrent BOT          
45 Not done STAH BSO Serous 2C  Yes 36 
Palpable pelvic 
mass on vaginal 
examination at 
routine follow-up 
3 years post-op 
SBOT 
Laparotomy – excision of 
recurrent BOT 
Alive  201 
27 15  Left Ovarian Cystectomy Serous 1C  No 30 
Complex ovarian 
cystic structure 
on routine follow 
up pelvic 
ultrasound 
SBOT 
Laparotomy - Unilateral 
oophorectomy + 
omentectomy + biopsy of 
contralateral ovary 
Alive 63 
25 420 
Unilateral oophorectomy, 
omentectomy, contralateral 
ovarian biopsy, pelvic 
peritonectomy 
(Residual disease) 
Serous 3A  Yes 
3 
(Progressive 
disease) 
MRI 1 month 
post-op: cystic 
mass 
SBOT 
Laparotomy - 
oophorectomy and 
excision of mass from 
pelvic side wall 
Alive 32 
44 355 
Unilateral oophorectomy, 
omentectomy, contralateral 
ovarian biopsy  
Serous 1C  No 36 
Complex ovarian 
cystic structure 
on routine follow 
up pelvic 
ultrasound 
SBOT 
TLH, unilateral 
oophorectomy, 
omentectomy 
Alive 43 
47 78 TAH BSO omentectomy Mucinous 1C  No 20 
Incidental finding 
of ovarian 
remnant 
containing BOT 
at time of hernia 
repair  
MBOT No further treatment Alive 32 
Malignant Transformation                 
Overall 
survival 
(months) 
39 263 
Prophylactic BSO for 
BRCA1 carrier status 
Serous 1A  Yes 8 
Abdominal pain 
and distension 
High Grade Serous 
Primary Peritoneal 
Carcinoma  
Carbotaxol chemotherapy 
Died of 
disease 
58 
53 3230 
TAH, BSO, omentectomy 
(Residual disease) 
Serous 2B  No 
5 
(Progressive 
disease) 
Abdominal 
distension and 
pain 
CT: disseminated 
malignancy 
Carbotaxol chemotherapy 
Died of 
disease 
50 
62 39 TAH BSO Omentectomy Serous 3C no 21 
Abdominal pain 
and distension 
Low grade serous 
carcinoma 
Laparotomy - 
omentectomy, transverse 
colectomy, small bowel 
resection 
Alive 
In 
remission 
                                     
56                    
37 1060 
Unilateral oophorectomy, 
omental biopsy  
(Equivocal original 
pathology) 
  
Serous 3B  Yes 
1 
(Progressive 
disease) 
  
Abdominal pain 1 
month post-op 
BOT with invasion 
Laparotomy TAH, 
unilateral oophorectomy, 
omentectomy 
Alive in 
remission 
 136             
70 85 TAH BSO, omentectomy Mucinous 1A  No 7 Abdominal pain 
CT: disseminated 
malignancy 
Carbotaxol chemotherapy 
Died of 
disease 
41 
22 32 
Unilateral oophorectomy, 
omental biopsy, contra-
lateral ovarian biopsy, 
appendicectomy, para-aortic 
node sampling 
Mucinous 1A  No 7 
Abdominal 
distension during 
pregnancy 
Sertoli-leydig tumour 
(Unrelated malignancy) 
Laparotomy -debulking 
Died of 
disease 
8 
Table 2
30 Not done 
Right cystectomy  
(Equivocal pathology) 
Completion surgery: TAH 
BSO (all specimens 
negative) 
Mucinous 1C  No 35 Abdominal pain  
Metastatic mucinous 
adenocarcinoma 
Platinum chemotherapy 
Died of 
disease 
39 
 
Table 2: Detailed patient demographics of 12 patients with recurrent BOT or malignant transformation 
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Open Access License Agreement 
This OPEN ACCESS LICENSE AGREEMENT (this “Agreement”), 
dated as of. 
  _____________________________________ 
DATE 
 
 (the “Effective Date”), by and between Wolters Kluwer 
Health, Inc., operating as Medical Research / Lippincott 
Williams & Wilkins, a Delaware corporation, having its 
principal place of business at Two Commerce Square, 2001 
Market Street, Philadelphia, PA 19103 (the “Publisher”), and 
the corresponding author listed on Schedule A to this 
Agreement (the “Author”, and together with the Publisher, 
the “Parties”). 
1. Grant of License 
The Author hereby grants to the Publisher and its Affiliates 
the exclusive, worldwide, royalty free, perpetual (for the 
duration of the applicable copyright) right and license to use 
the Work for all commercial or educational purposes, 
including, but not limited to, publishing, reproducing, 
marketing, distributing (themselves and through distributors), 
sublicensing, and selling copies of the Work throughout the 
world for the Term.  If the Author is a United States 
government employee, such license grant shall be limited to 
the extent the Author is able to grant such license. 
2. Warranties, Indemnification, and Limitation of Liability 
a. The Author represents and warrants that: 
(i) it has the right and power to enter into this 
Agreement, to grant the rights and licenses granted pursuant 
to this Agreement, and to perform all of its other obligations 
contained in this Agreement; 
 
(ii) it has not previously assigned, transferred or 
otherwise encumbered the rights or licenses granted 
pursuant to this Agreement; and that the person executing 
this Agreement on the Author’s behalf is authorized to do 
so; 
(iii) the Work and the licenses granted herein do not 
and will not infringe upon, violate or misappropriate any 
intellectual property rights or any other proprietary right, 
contract or other right or interest of any third party;  
(iv) if the Work is a multi-authored Work, the Author 
has obtained written permission from each author of the 
Work to enter into this Agreement on behalf such author, 
and each such author has read, understands and has agreed 
to the terms of this Agreement; and 
(v)  the Author has obtained any necessary releases 
and permissions to quote from other sources in the Work 
and to include any works and materials in the Work and all 
such releases and permissions are in full force and effect. 
b. The Author hereby indemnifies the Publisher and its 
directors, officers, employees, agents, and representatives 
and agrees to defend and hold them harmless from and 
against any and all liability, damage, loss, costs or expenses 
(including reasonable attorney’s fees and costs of settlement) 
incurred by any such party arising out of, or relating to any 
misrepresentation in, or breach or alleged breach of the 
Author’s representations or warranties in this Agreement.  If 
the Author fails to promptly or diligently pursue any defense 
of any indemnified party, the indemnified parties, or any of 
them, may assume such defense at the Author’s expense.  
The obligations of this indemnification will survive any 
termination or expiration of this Agreement. 
c. The Publisher represents and warrants that it has the right 
and power to enter into this Agreement and to perform its 
obligations contained in this Agreement, and that the person 
executing this Agreement on the Publisher’s behalf is 
authorized to do so. 
License to Publish
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d. The Publisher hereby indemnifies the Author and agrees 
to defend and hold the Author harmless from and against 
any and all liability, damage, loss, costs or expenses 
(including reasonable attorney’s fees and costs of settlement) 
incurred by the Author arising out of, or relating to any 
misrepresentation in, or breach or alleged breach of the 
Publisher’s representations or warranties in this Agreement.  
If the Publisher fails to promptly or diligently pursue any 
defense of the Author, the Author may assume such defense 
at the Publisher’s expense.  The obligations of this 
indemnification will survive any termination or expiration of 
this Agreement. 
e. EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, 
NEITHER PARTY MAKES ANY OTHER, AND HEREBY 
DISCLAIMS ALL OTHER, REPRESENTATIONS AND 
WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, 
STATUTORY OR OTHERWISE, INCLUDING, WITHOUT 
LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, 
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, 
OR THE ABSENCE OF LATENT OR OTHER DEFECTS, 
ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, 
WHETHER OR NOT DISCOVERABLE. 
f.  EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, 
IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER 
PARTY BASED UPON ANY LEGAL THEORY FOR ANY SPECIAL, 
INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR EXEMPLARY 
DAMAGES ARISING OUT OF THIS LICENSE OR THE USE OF 
THE WORK, EVEN IF A PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. 
3. Creative Commons License.  
Creative Commons Licenses are subject to items selected in 
item 1, 2 and 3 in the Schedule B.   
 
a. CCBY-NC-ND – NonCommercial-NonDerivitives Creative 
Commons License 
 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution-
NonCommercial-NoDerivs 4.0 Creative Commons License, as 
currently displayed at 
http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode 
(the “CC BY-NC-ND”).  The Author acknowledges and agrees 
that that Publisher is the exclusive “Licensor”, as defined in 
the CC BY-NC-ND, of the Work and that the Publisher may 
make the Work freely available to all users under the terms 
of the CC BY-NC-ND. 
b. CCBY – Creative Commons License 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution 4.0 
Creative Commons License, as currently displayed at 
http://creativecommons.org/licenses/by/4.0/legalcode (the 
“CC BY”).  The Author acknowledges and agrees that that 
Publisher is the exclusive “Licensor”, as defined in the CC BY, 
of the Work and that the Publisher may make the Work 
freely available to all users under the terms of the CC BY. 
c. CCBY-NC – NonCommercial Creative Commons License 
The Author acknowledges and agrees that the Work will be 
published by the Publisher in (the “Journal”) and made freely 
available to users under the terms of the Attribution-
NonCommercial 4.0 Creative Commons License, as currently 
displayed at http://creativecommons.org/licenses/by-
nc/4.0/legalcode (the “CC BY-NC”).  The Author 
acknowledges and agrees that that Publisher is the exclusive 
“Licensor”, as defined in the CC BY-NC, of the Work and that 
the Publisher may make the Work freely available to all users 
under the terms of the CC BY-NC. 
4. Royalties.  
The Author acknowledges and agrees that this Agreement 
entitles the Author to no royalties or fees.  To the maximum 
extent permitted by law, the Author waives any and all rights 
the Author may have to collect royalties or other fees in 
relation to the Work or in respect of any use of the Work by 
the Publisher or its sublicensees. 
 
 
5. Miscellaneous. 
a. Assignment.  This Agreement may not be assigned or 
transferred, in whole or in part, by either party without the 
prior written consent of the other party.  Notwithstanding 
the above, the Publisher may assign this Agreement without 
the written consent of the Author (i) to an entity succeeding, 
whether by sale, merger or other corporate reorganization, 
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to substantially all of the Publisher’s assets and business 
activity, or (ii) to a corporation or organization that obtains 
the right to publish the Journal from the Publisher.  The 
Publisher may assign this Agreement to any of its affiliates.  
This Agreement will be binding upon and inure to the 
benefit of the parties hereto and their respective successors 
and permitted assigns. 
b. Counterparts.  This Agreement may be executed in two or 
more counterparts, each of which shall be deemed an 
original, but all of which together shall constitute one and 
the same document.  Facsimile or Portable Document 
Format (PDF) signatures will be deemed original signatures 
for purposes of this Agreement. 
c. Entire Agreement; Amendment.  This Agreement sets forth 
the entire agreement of the parties on the subject hereof 
and supersedes all previous or contemporaneous oral or 
written representations or agreements relating to the rights 
and duties provided herein, and may not be modified or 
amended except by written agreement of the parties. 
d. Force Majeure.  Neither party shall be liable for any 
default or delay on its part in performing any obligation 
under this Agreement if such default or delay is caused by 
natural disaster, accident, war, civil disorder, strike or any 
other cause beyond the reasonable control of such party.  In 
the event that either party is prevented by such an 
occurrence or circumstance for a period of more than ninety 
(90) days from fulfilling its obligations under this Agreement, 
the other party may terminate this Agreement upon thirty 
(30) days’ written notice. 
e. Governing Law.  This Agreement shall be governed in all 
respects according to the laws of the State of New York 
without giving effect to the principles of conflict of law 
thereof. 
f. Headings.  All headings are for reference purposes only 
and shall not affect the meaning or interpretation of any 
provision hereof. 
g. Severability.  If any provision of this Agreement is held to 
be illegal, invalid, or unenforceable under the present or 
future laws, then such provision shall be revised by a court 
of competent jurisdiction to be enforceable if permitted 
under applicable law, and otherwise shall be fully severable.  
In any event, this Agreement shall be construed and 
enforced as if such illegal, invalid, or unenforceable provision 
had never comprised a part of this Agreement, and the 
remaining provisions of this Agreement shall remain in full 
force and effect and shall not be affected by the illegal, 
invalid, or unenforceable provision or by its severance from 
this Agreement. 
h. Status of the Parties.  The parties are independent 
contractors.  Nothing in this Agreement is intended to or 
shall be construed to constitute or establish any agency, 
joint venture, partnership or fiduciary relationship between 
the parties, and neither party has the right or authority to 
bind the other party nor shall either party be responsible for 
the acts or omissions of the other. 
i. Waiver; Amendment.  The waiver by either party of or the 
failure by either party to claim a breach of any provision of 
this Agreement shall not be, or be held to be, a waiver of 
any subsequent breach or affect in any way the further 
effectiveness of any such provision.  No term or condition of 
this Agreement may be waived except by an agreement by 
the parties in writing. 
j. Waiver of Jury Trial.  EACH PARTY HEREBY WAIVES ITS 
RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY 
DISPUTE OR LEGAL PROCEEDING ARISING OUT OF THIS 
AGREEMENT OR THE SUBJECT MATTER HEREOF. 
 
[Signature Page Follows] 
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Schedule A 
This Schedule A must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule A is completely filled out. 
   
Article Tracking # 
 
   
Article Title (the “Work”) 
 
   
Corresponding Author Name (the “Author”) 
 
   
Copyright Owner’s Name 
 
   
Name of Journal in which Work is to be Published 
 
 
Schedule B 
This Schedule B must be completed by Author in its entirety.  The Publisher is unable to publish the Work unless 
this Schedule B is completely filled out. 
MANDATED FUNDING POLICY DISCLOSURE 
 
1.   Choose a funder from the drop down list. If any of the following are selected please complete Item 2.  
 
 
 
 
NOTE:   If you are a World Health Organization Employee and are required to publish under the Creative Commons CCBY  IGO 
license,  then do not complete  this  form.  Instead, please contact  the Editorial Office  for  the separate WHO Employee  license 
agreement.  
 
2.  If you have selected funding from the above list in 1., please disclose the Open Access option to which the 
Work will be subject. Selecting “Gold Route” will ensure that your work is published under the Creative 
Commons CCBY license. 
□  Gold route 
□  Green route 
NOTE:  If the “Gold” route has been selected, Section 3.b. of the Agreement will apply to the Work, and neither Section 3.a. nor 
Section 3.c. of the Agreement will apply to the Work.  If the “Green” route has been selected, Section 3.c. of the Agreement will 
apply to the Work after an embargo, and neither Section 3.a. nor Section 3.b. of the Agreement will apply to the Work.  
Please select the appropriate funder
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3.  □  This Schedule B is inapplicable to the Work. 
NOTE: If author has selected Item 3, Section 3.a. on the Agreement will apply to the Work, and neither Section 3.b. nor Section 
3.c. of the Agreement will apply to the Work.     
GOVERNMENT EMPLOYEES 
4.  □  This work was created in the course of an author’s employment by the United States Government 
 If the Work or a portion of it has been created in the course of any author's employment by the United States 
Government, check the "Government" box at the end of this form. A work prepared by a government employee as 
part of his or her official duties is called a "work of the U.S. Government" and is not subject to copyright. If it is not 
prepared as part of the employee's official duties, it may be subject to copyright.  
If “Government” is chosen, please do not choose a Creative Commons License. The work will be published with 
“Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. 
Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the 
United States Code is not available. As such, copyright does not extend to the contributions of employees of the 
Federal Government.” 
 
NOTE: If author has selected Item 4, Section 3. on the Agreement will not apply to the Work.     
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SIGNATURE PAGE 
The Corresponding Author acknowledges and agrees that the Corresponding Author is entering into, and has 
executed, the Agreement on behalf of the Corresponding Author and each other author named as 
contributing to the Article (each such author, an “Author”, and collectively, the “Authors”). The Corresponding 
Author represents and warrants that the Corresponding Author has obtained permission from each Author to 
enter into the Agreement on behalf of such Author and the Corresponding Author and each Author has read, 
understands, and has agreed to the terms of the Agreement, including, without limitation, the terms 
contained in the Agreement with respect to authorized reuse of the Article.  
 
IN WITNESS WHEREOF, the Author has executed this License, effective as of the Effective Date. 
 
______________________________________________________________________ 
PRINT NAME 
 
______________________________________________________________________ 
SIGNATURE 
 
Important Note: Once you electronically sign this form, you will not be able to make any additional changes to it. 
To electronically sign this form, click the signature field above and provide the information requested in the dialog boxes. 
 
